The effect of artichoke leaf extract supplementation on lipid profile of chronic kidney disease patients; a double-blind, randomized clinical trial

Introduction: hyperlipidemia is considered a prominent risk factor for coronary heart disease. coronary heart disease is the most common cause of mortality and morbidity in chronic kidney disease (ckd) patients.objectives: the aim of this study was to evaluate the effects of artichoke leaf extract (ale) supplementation on the lipid profile of ckd patients.patients and methods: a randomized, double-blind, placebo-controlled clinical trial was conducted in 38 ckd subjects (gfr<60 and >15 ml/min/1.73 m2) with hypercholesterolemia (total cholesterol ≥ 200 mg/dl or low-density lipoprotein cholesterol [ldl-c] ≥ 110 mg/dl). the intervention group received an artichoke capsule (320 mg) and an indistinguishable placebo was given to the control group twice daily for 6 weeks. lipid profile and appetite were assessed at week 8 and the results were compared with the baseline data.results: ale supplementation was correlated with a statistically significant decrease in mean total cholesterol (p = 0.028) and ldl-c (p = 0.005) compared to the control group. the two groups did not show a significant difference in high-density lipoprotein-cholesterol (p = 0.071) and triglyceride levels (p = 0.22). there was a statistically significant difference in appetite between the two groups (p = 0.016).conclusion: this randomized controlled trial demonstrated that consumption of ale supplement may improve appetite and lipid profile in ckd patients.trial registration: this rct has been approved by iranian registry of clinical trials identifier: irct2016021622689n3; http://en.irct.ir/trial/19516, ethics committee reference number; ir.tums.rec.1394.1531).